Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
US Department of Justice
Colorcon
Harvard Business School
US Army
Fuji
Citi
Accenture

Generated: December 17, 2018

DrugPatentWatch Database Preview

SPRYCEL Drug Profile

« Back to Dashboard

When do Sprycel patents expire, and when can generic versions of Sprycel launch?

Sprycel is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and nineteen patent family members in thirty-nine countries.

The generic ingredient in SPRYCEL is dasatinib. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dasatinib profile page.

Drug patent expirations by year for SPRYCEL
Pharmacology for SPRYCEL
Medical Subject Heading (MeSH) Categories for SPRYCEL
Synonyms for SPRYCEL
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
2-{6-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide
2359AH
302962-49-8
302962-49-8 pound not863127-77-9
49310-EP2270008A1
49310-EP2292617A1
49310-EP2311840A1
5-Thiazolecarboxamide, monohydrate
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-
5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-
A-2429
AB0066750
AB01273956_03
AB01273956-01
AB01273956-02
AC-22749
AC1MI3ET
AC1Q2P0C
AK-47532
AKOS015902363
AM20080877
AmbotzLS-1203
AN-5289
anh. dasatinib
anhydrous dasatinib
ANW-43935
AOB87355
API0002220
AX8035158
BCB03_000715
BCP9000589
BCPP000263
BDBM13216
BMS 345825
BMS 354825
BMS 354825|||Sprycel
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825-03
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS-354825;BMS354825;BMS 354825
BMS354825
BR-47532
BRD-K49328571-001-07-7
CAS-302962-49-8
CD0138
CHEBI:49375
CHEMBL1421
cid_3062316
CS-0100
CTK8B4120
D-3307
D03658
D0E6XR
Dasatinib
Dasatinib - BMS-354825
dasatinib (anh.)
Dasatinib (anhydrous)
Dasatinib (BMS-354825)
Dasatinib (INN)
Dasatinib (USAN)
Dasatinib [USAN:INN]
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib BMS-354825
Dasatinib, BMS 354825
Dasatinib,BMS-354825
Dasatinib;
dasatinibum
DB01254
DR003007
DSSTox_CID_20979
DSSTox_GSID_40979
DSSTox_RID_79608
DTXSID4040979
EN002710
EX-A401
FC0026
FT-0084503
FT-0650671
GS-6548
GTPL5678
HE333223
HMS2043N05
HMS3244A05
HMS3244A06
HMS3244B05
HMS3265C19
HMS3265C20
HMS3265D19
HMS3265D20
HMS3654K05
HY-10181
I14-1972
KB-274688
KB-76415
Kinome_3650
KS-0000027F
LS-186641
LS-187028
LS-187773
MFCD11046566
MLS003915609
MLS004774145
MLS006010904
MolPort-003-846-143
N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide
n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thia
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NCGC00181129-02
NCGC00181129-03
NCGC00181129-05
NCGC00181129-06
NSC-732517
NSC-759877
NSC732517
NSC759877
Pharmakon1600-01502275
Q-101345
QCR-106
RTR-013021
RTR-021205
s1021
SC-22079
SCHEMBL8226
SMR002529551
Sprycel (Bristol Meyers)
SPRYCEL (TN)
Spyrcel
SR-00000000554
SR-00000000554-5
ST2419212
SYN1036
Tox21_112736
Tox21_112736_1
TR-013021
TRA0075817
UNII-X78UG0A0RN
X78UG0A0RN
Z2786158251
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
ZINC3986735

US Patents and Regulatory Information for SPRYCEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-006 Oct 28, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SPRYCEL
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for SPRYCEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/003 Ireland ➤ Try a Free Trial PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120
90004-8 Sweden ➤ Try a Free Trial PRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120
0567 Netherlands ➤ Try a Free Trial PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
US Department of Justice
Colorcon
Harvard Business School
US Army
Fuji
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.